- News Home
5 December 2013 11:26 am ,
Vol. 342 ,
An animal rights group known as the Nonhuman Rights Project filed lawsuits in three New York courts this week in an...
Researchers have been hot on the trail of the elusive Denisovans, a type of ancient human known only by their DNA and...
Thousands of scientists in the Russian Academy of Sciences (RAS) are about to lose their jobs as a result of the...
Dyslexia, a learning disability that hinders reading, hasn't been associated with deficits in vision, hearing, or...
Exotic, elusive, and dangerous, snakes have fascinated humankind for millennia. They can be hard to find, yet their...
Researchers have sequenced and analyzed the first two snake genomes, which represent two evolutionary extremes. The...
Snake venoms are remarkably complex mixtures that can stun or kill prey within minutes. But more and more researchers...
At age 30, Dutch biologist Freek Vonk has built up a respectable career as a snake scientist. But in his home country,...
- 5 December 2013 11:26 am , Vol. 342 , #6163
- About Us
Settlement Ends Lawsuits Against Prominent Researcher
4 September 2012 12:29 pm
Two lawsuits filed against the president of Memorial Sloan-Kettering Cancer Center in New York City have been settled, the parties announced on Friday. Prominent researcher Craig Thompson had faced allegations from the University of Pennsylvania (Penn) and the research arm of its cancer center, The Leonard and Madlyn Abramson Family Cancer Research Institute, that he concealed his involvement in a biotechnology company and failed to share intellectual property from his discoveries with the university, as required. Thompson had worked at the Abramson institute for 12 years.
The parties have been tight-lipped since the first lawsuit was filed in December. (The second came in February.) It's not clear whether one side came out ahead, as terms of the settlement are hazy. Penn and one of its opponents in the suit, Agios Pharmaceuticals (which Thompson helped found), announced that they had entered into a licensing agreement involving intellectual property of cancer diagnostics.
The lawsuits were unusual both for Thompson's stature and for their sweeping allegations. The Abramson cancer research institute charged that damages were estimated to "exceed $1 billion." In addition to Thompson, the suit named Agios and another company, Celgene Corp., as defendants. Celgene was not a defendant in the second lawsuit filed by Penn, however.
A glimpse of Thompson's position came in April, when his attorney Allan Arffa sought to dismiss the lawsuit filed by the cancer institute (but not the one filed by Penn). In documents filed with the court, Arffa described the cancer institute's assertions as "scattershot and disorganized," and argued that Thompson had disclosed his relevant discoveries to Penn. Arffa also argued that although Thompson directed the cancer research institute, his employer was the University of Pennsylvania, meaning that the Abramson institute's "rights to any intellectual property based on research it funds derive solely from Penn’s rights."
Attorneys in the case did not respond to requests for comment.